NASDAQ:RLMD Relmada Therapeutics (RLMD) Stock Price, News & Analysis $0.60 -0.02 (-2.43%) Closing price 04:00 PM EasternExtended Trading$0.60 0.00 (-0.18%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Relmada Therapeutics Stock (NASDAQ:RLMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Relmada Therapeutics alerts:Sign Up Key Stats Today's Range$0.59▼$0.6450-Day Range$0.28▼$0.8352-Week Range$0.24▼$4.47Volume185,265 shsAverage Volume968,382 shsMarket Capitalization$19.95 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingHold Company Overview Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. Read More Relmada Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks96th Percentile Overall ScoreRLMD MarketRank™: Relmada Therapeutics scored higher than 96% of companies evaluated by MarketBeat, and ranked 59th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingRelmada Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageRelmada Therapeutics has received no research coverage in the past 90 days.Read more about Relmada Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Relmada Therapeutics are expected to grow in the coming year, from ($2.73) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relmada Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relmada Therapeutics is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelmada Therapeutics has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Relmada Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.64% of the float of Relmada Therapeutics has been sold short.Short Interest Ratio / Days to CoverRelmada Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Relmada Therapeutics has recently decreased by 38.45%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRelmada Therapeutics does not currently pay a dividend.Dividend GrowthRelmada Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.45 Percentage of Shares Shorted2.64% of the float of Relmada Therapeutics has been sold short.Short Interest Ratio / Days to CoverRelmada Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Relmada Therapeutics has recently decreased by 38.45%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.47 News SentimentRelmada Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Relmada Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for RLMD on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Relmada Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $286,332.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.70% of the stock of Relmada Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.24% of the stock of Relmada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Relmada Therapeutics' insider trading history. Receive RLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RLMD Stock News HeadlinesRelmada Therapeutics Inc News (RLMD) - Investing.com4 hours ago | investing.comRLMD Relmada Therapeutics, Inc. - Seeking AlphaJuly 2 at 8:36 AM | seekingalpha.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.July 2 at 2:00 AM | American Alternative (Ad)Relmada Therapeutics' Market Cap Drops To US$22m Leaving Insiders With LossesJune 28, 2025 | uk.finance.yahoo.comRelmada Therapeutics, Inc. (RLMD) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRLMD - Relmada Therapeutics Inc Executives - MorningstarJune 24, 2025 | morningstar.comMRelmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-UrologyJune 17, 2025 | globenewswire.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comSee More Headlines RLMD Stock Analysis - Frequently Asked Questions How have RLMD shares performed this year? Relmada Therapeutics' stock was trading at $0.52 at the beginning of 2025. Since then, RLMD stock has increased by 15.8% and is now trading at $0.6020. View the best growth stocks for 2025 here. How were Relmada Therapeutics' earnings last quarter? Relmada Therapeutics, Inc. (NASDAQ:RLMD) posted its quarterly earnings results on Monday, May, 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.27. Read the conference call transcript. How do I buy shares of Relmada Therapeutics? Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Relmada Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Relmada Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), ServiceNow (NOW), GE Aerospace (GE) and Adobe (ADBE). Company Calendar Last Earnings5/12/2025Today7/02/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLMD CIK1553643 Webwww.relmada.com Phone(786) 629-1376FaxN/AEmployees10Year Founded2004Price Target and Rating Average Stock Price Target$5.00 High Stock Price Target$13.00 Low Stock Price Target$1.00 Potential Upside/Downside+705.2%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($2.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.98 million Net MarginsN/A Pretax MarginN/A Return on Equity-181.26% Return on Assets-151.23% Debt Debt-to-Equity RatioN/A Current Ratio5.29 Quick Ratio5.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.18 per share Price / Book0.53Miscellaneous Outstanding Shares33,190,000Free Float26,321,000Market Cap$20.61 million OptionableOptionable Beta0.60 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:RLMD) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.